有投资者向复星医药提问, 请问下复星医药管理层截止2024年三季度CAR-T历年接受治疗人数?奕凯达每年需要治疗多少患者,复星凯瑞才能实现盈亏平衡?公司是否有通用CAR-T研发项目及其进展?如何看待,复星凯特前总裁王立群博士从公司离职后创立了“星奕昂(上海)生物科技有限公司?复星对高级研发人才是否不够重视?高管团队是否商业化背景的人才过多?研发背景的人才过少?针对高级研发人才公司是否签署竞业协议或...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.